Market Overview

NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara by EC

NPS Pharmaceuticals (NASDAQ: NPSP) today announced that the European
Commission has granted orphan drug designation to Natpara® (recombinant
human parathyroid hormone (rhPTH[1-84]) for the treatment of
hypoparathyroidism. Natpara is a bioengineered replacement for
endogenous parathyroid hormone (PTH) that NPS has developed for the
treatment of hypoparathyroidism, a rare endocrine disorder in which the
body produces insufficient levels of parathyroid hormone, a principal
regulatory of the body's mineral homeostasis. Orphan drug designation in
the European Union (EU) is given to products that are designed for the
diagnosis, prevention or treatment of rare diseases that are
life-threatening or chronically debilitating.

See full press release

Posted-In: News Guidance FDA Management Global

 

Related Articles (NPSP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters